I thank the committee for the time that it has taken so far to read the evidence and understand the scale of the issue. I also thank you for reading the personal stories, which you will agree are sad and tragic, given that medical help is available in countries other than the UK—for example, Armour Thyroid is prescribed in Belgium.
It is unfortunate that the petitioner, Lorraine Cleaver, cannot be here today. She has submitted a note that highlights her dependency on desiccated thyroid hormone, which—as members will know—many others rely on. It is worrying that, although people were previously able to buy desiccated thyroid hormone from the USA, the Food and Drug Administration now seems to be demanding prescriptions to ship it into the UK. The question needs to be asked why there has been that sudden change. Lorraine Cleaver wonders whether that has happened at the instigation of the UK. There are questions to be answered on that.
Desiccated thyroid hormone was the normal treatment prior to the patenting of T4, and it literally brings people back to life. General practitioners can prescribe desiccated thyroid hormone as long as they take personal responsibility for the treatment. It would be better if people did not have to buy it from the US, but could instead have it prescribed by their GPs if they meet the guidelines, and if they had tried the licensed product first. A lot of people feel that they are being denied health and that their GPs might be breaking the hippocratic oath by denying them treatment that would—and has been shown to—help them, meaning that they have to purchase it themselves from abroad.
There are no financial benefits from desiccated thyroid hormone for the pharmaceutical companies. That may be why, in the Government’s letter to you, when it talks about T3, it says:
“it may be that companies do not see it in their economic interests to enter into such a small market.”
That is a possible reason why there is only one pharmaceutical company making T3. As we know, there were problems because of that when there was no supply of T3. There was another shortage in March—I do not know whether you know about that, convener—which was resolved, but it highlights the fact that there is only one supplier. Some of the evidence that the committee has received for this meeting also shows close ties between pharmaceutical companies and the medical profession.
I understand from Lorraine Cleaver’s submission that she met David Cline and is pleased to have been given the opportunity to contribute to the listening exercise. It is good that evidence is being gathered on a subject that affects so many people in Scotland. However, I am not entirely clear—I do not know whether the committee is—how much of that work will be focused specifically on thyroid problems, which is a question that the committee asked before. I would be happy to contribute to that exercise in any way whatever, and I hope that the fact that it is taking place will be publicised.
I respectfully ask the committee to consider keeping the petition open at least until the listening exercise is finished. I also ask that the committee give some consideration to holding its own inquiry with a focus on gathering the available clinical evidence and taking evidence from patients including those who are parked on T4 to find out whether they are well on T4 and whether they are suffering other symptoms. Finally, I ask the committee to consider why GPs will not prescribe desiccated thyroid hormone when it was previously the safe way to treat underactive thyroid conditions, and brought patients back to life and kept them economically active. There are a lot of things that an inquiry could look into, which would benefit many patients and perhaps also the NHS, in the long run.